 Aeterna Zentaris was one of my previous winners, but a disappointing commercial launch for their flagship product, Macrilen, caused the share price to bleed for most of 2020. The company has been making deals left and right, which brought the share price from around 0.30 to over 3.00 in a few months. I review some of these deals. 